<DOC>
	<DOCNO>NCT01772693</DOCNO>
	<brief_summary>This feasibility study evaluate safety initial effectiveness unilateral ExAblate thermal ablation Vim thalamic nucleus subject suffer medication-refractory , idiopathic , tremor-dominant PD , use ExAblate Transcranial system compare Sham Vim thalamotomy procedure . Data collect establish basic safety type treatment basis later study evaluate full clinical efficacy . The Sham treatment data use evaluate placebo effect treatment .</brief_summary>
	<brief_title>ExAblate Transcranial MR Guided Focused Ultrasound Treatment Parkinson 's Disease</brief_title>
	<detailed_description>Subjects sign inform consent pas eligibility criterion randomize treatment assignment . During treatment , assign treatment ( ExAblate Transcranial Sham ExAblate Transcranial ) deliver . Subjects follow blinded fashion three ( 3 ) month . After 3-month assessment , subject unblinded told treatment assignment . Subjects receive Sham ExAblate Transcranial treatment still meet criterion cross receive active ExAblate Transcranial treatment . Subjects follow two ( 2 ) year . Follow-up 1 week , 1 month , 3 month , 6 month , 9 month , 12 month two ( 2 ) year include Unified Parkinson 's Disease Rating Scale ( UPDRS ) scoring , mental cognitive functional testing questionnaire .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Men woman , age 30 year old Subjects able willing give inform consent able attend study visit Subjects diagnosis idiopathic PD confirm clinical history examination movement disorder neurologist site Subject demonstrate severe rest tremor postural/action measure UPDRS Subject exhibit significant disability PD tremor despite medical treatment Subjects stable dose PD medication 30 day prior study entry Subject able communicate sensation ExAblate Transcranial procedure Subjects unstable cardiac status Subjects exhibit behavior ( ) consistent ethanol substance abuse Severe hypertension Subjects standard contraindication MR image nonMRI compatible implant metallic device include cardiac pacemaker , size limitation , etc . Known intolerance allergy MRI contrast agent include advanced kidney disease severely impaired renal function Significant claustrophobia manage mild medication Current medical condition result abnormal bleeding and/or coagulopathy Receiving anticoagulant ( e.g . warfarin ) antiplatelet ( e.g . aspirin ) therapy within one week focus ultrasound procedure drug know increase risk hemorrhage History intracranial hemorrhage History multiple stroke , stroke within past 6 month Subjects able willing tolerate require prolonged stationary supine position treatment Are participate participate another clinical trial last 30 day Subjects unable communicate investigator staff Subjects history seizure within past year Subjects brain tumor Subjects intracranial aneurysm require treatment arterial venous malformation ( AVMs ) require treatment Subjects deep brain stimulation prior stereotactic ablation basal ganglion</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ExAblate Transcranial MRgFUS</keyword>
</DOC>